The enduring impacts of early-life seizures on cognition and behavior are not attributed to neuronal loss but to disrupted hippocampus-prefrontal cortex network dynamics, heightened neuroinflammation, and altered dopaminergic transmission.

Disruption of the disease-associated synaptic adhesion molecule Neurexin1a in cortical excitatory neurons perturbs decision making and disrupts value-associated neural activity in downstream striatal circuits.

Loss of myelin integrity in the mouse forebrain perturbs executive functions, assessed by tests requiring normal motor performance.

Molecular genetic, cell culture as well as electrophysiological analyses reveal a C1ql2/Neurexin3(25b+)-dependent molecular pathway through which Bcl11b controls critical functions of adult hippocampal mossy fiber synapses.

Brain lactate and pH changes, identified as common features in diverse neuropsychiatric animal models, may represent transdiagnostic endophenotypes associated with cognitive impairment.

PASC (post-acute sequelae of SARS-CoV-2 infection) is an enduring and debilitating illness caused by a persistent virus that promotes inflammation, coagulation, and autoimmunity complications in millions of patients initially diagnosed with COVID-19, but with no known standardized treatment regimen.

Two genetically distinct Stxbp1 haploinsufficiency mouse models exhibit seizures and impairments in cognitive, psychiatric, and motor functions, representing robust preclinical models of STXBP1 encephalopathy with both construct and face validity.

High-definition anodal transcranial stimulation alleviated cognitive deficits, affected dopaminergic neurotransmission factors, increased expression of several neurotrophic factors involving brain-derived neurotrophic factor (BDNF), and activated hippocampal neurogenesis.

Frontal cortical circuit alterations and cognitive deficits identified in mouse genetic models are reversed by chemogenetic or optogenetic stimulation of the mesocortical dopamine circuit in an adolescent period.

Forniceal deep brain stimulation is a promising treatment for several neuropsychiatric disorders as it upregulates synaptic and neurogenesis-associated genes, normalizes genes misregulated in Rett syndrome mice, and regulates genes altered in intellectual disability and major depression.